Institut National De La Sante Et De La Recherche Medicale

Universite Claude Bernard – Lyon1

Other

Centre National De La Recherche Scientifique

Biomerieux, Inc.

Poxel

Ens-ecole Normale Superieure De Lyon

Edelris

Université´ D'aix-marseille

Centre National De La Recherche Scientifique-cnrs

Université Claude Bernard Lyon I

Ecole Normale Superieure De Lyon

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut De Recherche Pour Le Developpement

Enyo Pharma

Vincent Lotteau

Patrice Andre

Philippe Mangeot

Daniel Cravo

Didier Roche

Sophie Hallakou-Bozec

Amaury Patin

Marine Gilardone

Pauline Radreau

Glaucia Paranhos-Baccala

Benoît De Chassey

Florence Komurian-Pradel

Rolf Zinkernagel

Xavier De Lamballerie

Paul Klenerman

David Durantel

Sophie Hallakou-bozec

Marc Peschanski

Patrice Andr&eacute;

Anne Aublin-Gex

Marcus Groettrup

Pierre-Olivier Vidalain

Mathilde Girard

Laurene Meyniel-Schicklin

Antoine NOUGAIRÈDE

Pierre Oliver Vidalain

Christophe Ramiere

Benoît Lacombe

Julie Lucifora

Raphaël Darteil

Yves Louis Janin

Franck Touret

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection

The present invention relates to direct protein delivery with engineered micro vesicles.

Direct protein delivery with engineered microvesicles

The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3'-monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.

Methods and pharmaceutical compositions for inhibiting influenza viruses replication

The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.

Reprogrammation of eukaryotic cells with engineered microvesicles

The present invention relates to the use of L-&#x3b1;-lysophosphatidylcholine and/or an equivalent compound for the differentiation of monocytes into mature denditric cell. The present invention also relates to a method for differentiation monocytes into mature denditric cells according to which monocytes are provided in a medium suitable for their differentiation and L-&#x3b1;-lysophosphatidylcholine and/or an equivalent compound is added to said medium.

Use of L-&#x3b1;-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro

The invention concerns a method for differentiating precursor cells into mature dendritic cells, comprising placing the precursor cells in a medium suitable for their differentiation and adding to the medium, in a predetermined amount, at least one fraction of oxidized lipoproteins selected among oxidized very low density lipoproteins (VLDLs) and/or oxidized intermediate density lipoproteins (IDLs) and/or oxidized low density lipoproteins (LDLs). The precursor cells are preferably monocytes.

Use of oxidized lipoproteins for differentiation of precursor cells into mature dendritic cells

Complex of lipo-viro-particles, method of preparation and applications

The invention relates to the use of at least one compound that inhibits HIV (human immunodeficiency virus) protease, selected from ritonavir, saquinavir or one of the pharmaceutically acceptable salts thereof, in association with a pharmaceutically acceptable vehicle for the production of a medicament to modulate proteasome.

Use of HIV protease inhibiting compounds

Growing community of inventors

Lyons, France

Vincent Lotteau